A joint research initiative between the University of Kentucky and the University of Louisville.

Research Funding Opportunities


Department of Health and Human Services

Participating Organizations
National Institutes of Health (NIH) (http://www.nih.gov)

Components of Participating Organizations
National Cancer Institute (NCI) (http://www.cancer.gov)
Office of Dietary Supplements (NIH) (http://dietary-supplements.info.nih.gov)

Title: Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21)

Announcement Type
This is a reissue of PAR-06-451 <http://grants.nih.gov/grants/guide/pa-files/par-06-451.html> , which was previously released June 9, 2006.

NOTICE: Applications submitted in response to this FOA for Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related (R&R) forms and the SF424 (R&R) Application Guide.

APPLICATIONS MAY NOT BE SUBMITTED IN PAPER FORMAT.

This FOA must be read in conjunction with the application guidelines included with this announcement in Grants.gov/Apply for Grants <http://www.grants.gov/Apply>  (hereafter called Grants.gov/Apply).

A registration process is necessary before submission and applicants are highly encouraged to start the process at least 4 weeks prior to the grant submission date. See Section IV.

Program Announcement (PA) Number: PAR-08-025

Catalog of Federal Domestic Assistance Number(s)
93.393, 93.394, 93.395

Key Dates
Release/Posted Date: November 19, 2007
Opening Date: February 7, 2008 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent Receipt Date(s): A letter of intent is not required for the funding opportunity.
NOTE: On-time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization).
Application Submission/Receipt Date(s): March 7, 2008; July 9, 2008; November 7, 2008; March 9, 2009; July 9, 2009; November 9, 2009; March 9, 2010; July 9, 2010; November 9, 2010.
Application Review Date(s): June/July 2008; October/November 2008; February/March 2009; June/July 2009; October/November 2009; February/March 2010; June/July 2010; October/November 2010; February/March 2011.
Council Meeting Date(s): October 2008; January 2009; May 2009; October 2009; January 2010; May 2010; October 2010; January 2011; May 2011.
Earliest Start Date(s): December 2008; April 2009; July 2009; December 2009; April 2010; July 2010; December 2010, April 2011; July 2011.
Expiration Date: November 10, 2010

Due Dates for E.O. 12372

Not Applicable.

Additional Overview Content

Executive Summary

  • Purpose. This FOA is intended to promote translational research in new agent/modality development with timely exploitation of new cancer-relevant therapeutic and/or preventive strategies that involve defined molecular targets. Applications are solicited for pilot clinical trials exploring individual anticancer agents/modalities and/or their combinations in the context of specific molecular targets. Applicants may propose Phase 0, Phase I, Phase II, and/or other pilot cancer clinical trials. In addition, patient monitoring and laboratory correlative studies related to clinical trials may be proposed. Applications that explore complementary and alternative approaches for cancer prevention and/or treatment are also encouraged. Clinical trials proposed may be oriented on AIDS-associated malignancies and cancer-related nutritional interventions. Applicants must include the clinical protocol within the Appendix to ensure proper accelerated peer review with the goal of issuing new awards within 6 months of receipt of the grant application.
  • Mechanism of Support. This FOA will use the NIH exploratory/developmental (R21) grant mechanism for exploratory, pilot projects. Applicants planning to propose fully developed research projects supported by preliminary data should consider a related FOA (PA-07-356 <http://grants.nih.gov/grants/guide/pa-files/PA-07-356.html> ) that solicits applications for clinical therapeutic and preventive trials under the NIH research project (R01) grant mechanism.
  • Funds Available and Anticipated number of Awards: Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known.
  • Applications that do not propose a cancer clinical trial or patient monitoring or laboratory studies linked to a cancer clinical trial may be returned to applicants without being reviewed.
  • Budget and Project Period: The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $500,000 over an R21 2-year period, with no more than $250,000 in direct costs allowed in any single year.
  • An R21 award is not renewable.
  • Eligible Organizations: Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organizations (Other than Small Business); State Governments; U.S. Territory or Possession; Non-Domestic (non-U.S.) Entity (Foreign Organization); Regional Organization; Eligible agencies of the Federal government.
  • Eligible Project Directors/Principal Investigators (PDs/PIs): Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
  • Renewals. R21 awards are not renewable.
  • Resubmissions. Up to two resubmissions (formerly “revisions/amendments") of a previously reviewed R21 grant application may be submitted.
  • Application and Submission Information: Applicants may submit more than one application, provided each application is scientifically distinct.
  • Application Materials. See Section IV.1 <l>  for application materials. General Information. For general information on SF424 (R&R) Application and Electronic Submission, see these Web sites:
  • SF424 (R&R) Application and Electronic Submission Information at http://grants.nih.gov/grants/funding/424/index.htm; and
  • General information on Electronic Submission of Grant Applications at http://era.nih.gov/ElectronicReceipt/.
  • Telecommunications for the hearing impaired is available at: TTY 301-451-0088.
  • Special Receipt Dates: March 7, 2008; July 9, 2008; November 7, 2008; March 9, 2009; July 9, 2009; November 9, 2009; March 9, 2010; July 9, 2010; November 9, 2010.

For Futher Information: http://grants.nih.gov/grants/guide/pa-files/PAR-08-025.html


Expansion of Scientific Scope of PAR-08-025, Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21), to Include Symptom Management

Notice Number: NOT-CA-08-005

Key Dates
Release Date: December 27, 2007

Issued by
National Cancer Institute (NCI) (http://www.nci.nih.gov)

The purpose of this Notice is to inform prospective applicants that the programmatic scope of the Program Announcement PAR-08-025 <http://grants.nih.gov/grants/guide/pa-files/PAR-08-025.html> “Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21)” is expanded to include (and encourage) research projects related to managing symptoms associated with cancer and its treatment.

To reflect this scope expansion, the specified below passages in PAR-08-025 <http://grants.nih.gov/grants/guide/pa-files/PAR-08-025.html> are appended as indicated by highlighted text:

Executive Summary (the 5th sentence in the “Purpose” bullet): “Applications that explore complementary and alternative approaches for cancer prevention, treatment, and/or symptom management are also encouraged.”

Research Objectives (Purpose section): “The major purpose of this funding opportunity announcement (FOA) is to expedite clinical translation of basic research discoveries in cancer biology and cancer symptom management, through the development of novel anti-cancer and symptom reducing drugs, diagnostic tools, treatments, and preventions.”

Research Objectives (the last two sentences of Background section): “This FOA is intended to stimulate clinical translational research and accelerate the process of targeted cancer drug development for the treatment and prevention of cancer and the management of cancer symptoms associated with various disease stages and toxicities/adverse effects associated with different interventions. In addition, applications that explore complementary and alternative approaches for cancer prevention, treatment, and symptom management are also encouraged.”

Except for the above expansion of the scientific scope, all the other aspects of PAR-08-025 <http://grants.nih.gov/grants/guide/pa-files/PAR-08-025.html> remain unchanged.


Link to Full Announcement: http://grants.nih.gov/grants/guide/notice-files/NOT-CA-08-005.html

 

Department of Health and Human Services

Participating Organizations
National Institutes of Health (NIH) ( http://www.nih.gov <http://www.nih.gov/> )

Components of Participating Organizations
National Cancer Institute (NCI), ( http://www.cancer.gov <http://www.cancer.gov/> )

Title: Innovative Technologies for Molecular Analysis of Cancer (R21)

Key Dates
Release/Posted Date: January 9, 2008
Opening Date: February 11, 2008 (Earliest date an application may be submitted to Grants.gov).
Letters of Intent Receipt Dates: February 11, 2008; April 29, 2008; August 24, 2008.
NOTE: On-time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization).
Application Receipt Dates: March 11, 2008; May 29, 2008; September 24, 2008.
Peer Review Dates: May/June 2008; August/September 2008; January/February 2009.
Council Review Dates: August 2008; January 2009; May 2009.
Earliest Anticipated Start Dates: September 2008; April 2009; August 2009.
Additional Information To Be Available Date (URL Activation Date): Not Applicable.
Expiration Date: September 25, 2008

Announcement Type
This Funding Opportunity Announcement (FOA) is a reissue of RFA-CA-07-033 <http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-07-015.html> , which was previously released on January 4, 2007.

NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related (R&R) forms and the SF424 (R&R) Application Guide.

APPLICATIONS MAY NOT BE SUBMITTED IN PAPER FORMAT.

This FOA must be read in conjunction with the application guidelines included with this announcement in Grants.gov/Apply for Grants <http://www.grants.gov/Apply>  (hereafter called Grants.gov/Apply).

A registration process is necessary before submission and applicants are highly encouraged to start the process at least 4 weeks prior to the grant submission date. See Section IV <l> .

Request For Applications (RFA) Number: RFA-CA-08-006


For Assistance downloading this or any Grants.gov application package, please contact Grants.gov Customer Support at http://grants.gov/CustomerSupport


Catalog of Federal Domestic Assistance Number(s)
93.392, 93.393, 93.394, 93.395, 93.396

Due Dates for E.O. 12372

Not Applicable.

Additional Overview Content

Executive Summary

  • Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing exploratory research projects focused on the inception and early stage development of highly innovative cancer-relevant technologies. The emphasis of this FOA is on technically innovative molecular analysis tools with the potential to add a new quality to the investigations of the molecular basis of cancer (e.g., by facilitating the detection of cancer-related characteristics/alterations at the molecular and cellular levels of organization and function). These technologies may be intended for molecular analyses in vitro, in situ, and/or in vivo. Responsive “technologies” encompass relevant methods, techniques, tools, instrumentation, and devices (but not software or informatics solutions). This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Several IMAT FOAs of identical or closely related scientific scope using various funding mechanisms are available. To facilitate selection, a separate Notice in the NIH Guide for Grants and Contracts provides brief cross-comparison and links to all the IMAT FOAs. See NOT-CA-08-003 <http://grants.nih.gov/grants/guide/notice-files/NOT-CA-08-003.html> .
  • Mechanism of Support. This FOA will utilize the NIH R21 award mechanism for exploratory (pilot) research projects. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
  • Funds Available and Anticipated Number of Awards. The NCI intends to commit a total of approximately $3,000,000 to this FOA in fiscal year 2009 to award approximately 10 to 15 grants.
  • Budget and Project Period. The total project period for an application submitted in response to this FOA may not exceed 3 years. Direct costs are limited to $500,000 over an R21 3-year period, with no more than $200,000 in direct costs allowed in any single year.
  • The R21 is not renewable.
  • Eligible Institutions/Organizations. Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); and Non-Domestic (non-U.S.) Entity (Foreign Organization).
  • Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
  • Number of PDs/PIs. More than one PD/PI, or multiple PDs/PIs, may be designated on the application.
  • Renewals and Resubmissions. Applications can not be renewed by competing for additional project periods. Applicants may submit a “resubmission” application, but such application must include an “Introduction” addressing the previous peer review critique (Summary Statement).
  • Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct.
  • Application Materials. See Section IV.1 <l>  for application materials.
  • General Information. For general information on SF424 (R&R) Application and Electronic Submission, see these Web sites:
  • SF424 (R&R) Application and Electronic Submission Information at http://grants.nih.gov/grants/funding/424/index.htm; and
  • General information on Electronic Submission of Grant Applications at http://era.nih.gov/ElectronicReceipt/.
  • Hearing Impaired. Telecommunications for the hearing impaired is available at: TTY 301-451-0088.
  • Special receipt/submission dates are listed under “Key Dates <l> .”
  • Initial merit review convened by the Division of Extramural Activities, NCI.
  • Increased project duration to 3 years
  • Increased cumulative direct cost limit to $500,000

Link to Full Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-006.html
 
© 2007 Kentucky Lung Cancer Research Program